Literature DB >> 10547173

Meningococcal disease in a large urban population (Barcelona, 1987-1992): predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group.

N Barquet1, P Domingo, J A Caylà, J González, C Rodrigo, P Fernández-Viladrich, F A Moraga-Llop, F Marco, J Vázquez, J A Sáez-Nieto, J Casal, J Canela, M Foz.   

Abstract

CONTEXT: Studies on meningococcal disease in large urban communities have rarely been performed and are usually based on passive epidemiologic surveillance. Active surveillance may provide new insights.
OBJECTIVES: To determine epidemiologic, clinical, and bacteriological characteristics and predictors of dismal prognosis (death and sequelae) in meningococcal disease.
DESIGN: Prospective, population-based study.
SETTING: All the acute care hospitals (n = 24) in Barcelona, Spain. PATIENT: The 643 patients whose conditions were diagnosed from 1987 through 1992 were detected by 2 active surveillance methods. OUTCOME MEASURES: Incidence and notification to Public Health Service. Clinical and bacteriological features were determined. Dismal prognosis predictors were determined by logistic regression.
RESULTS: Average annual incidence was 6.41 per 100,000 inhabitants, with no clear trend of change (P = .08). Sensitivity of the Public Health Service surveillance system was 69.1%. Children younger than 10 years from the inner city were at higher risk than those from the highest income district (relative risk, 3.00; 95% confidence interval [CI], 1.84-5.06). Increasing annual incidence of serogroup C (0.82-1.29/100,000; P = .008) and decreasing incidence of serogroup B (5.11-2.82/100,000; P = .004) was noted. Average annual mortality was 0.40 per 100,000 inhabitants, while the annual average potential years of life lost was 18 per 100,000 inhabitants. Overall case-fatality rate was 6.4%. Independent predictors of death were hemorrhagic diathesis (odds ratio [OR], 63; 95% CI, 21-194), focal neurologic signs (OR, 10; 95% CI, 3-30), and age 60 years or older (OR, 6; 95% CI, 2-17), whereas preadmission antibiotic therapy was associated with favorable outcome (OR, 0.07; 95% CI, 0.02-0.3). Four percent of survivors presented with sequelae. Independent predictors of sequelae were hemorrhagic diathesis (OR, 21; 95% CI, 3-131), focal neurologic signs (OR, 16; 95% CI, 5-53), age 60 years or older (OR, 7; 95% CI, 2-26), and age between 15 and 59 years (OR, 5; 95% CI, 2-14), whereas preadmission antibiotic therapy had a protective effect (OR, 0.2; 95% CI, 0.04-0.5).
CONCLUSIONS: Active epidemiologic surveillance significantly improved detection of cases and allowed us to observe that meningococcal disease still causes much morbidity and mortality, especially among children living in the inner city. Hemorrhagic diathesis, focal neurologic signs, and age were independent predictors of dismal prognosis, whereas preadmission antibiotic therapy had a protective effect.

Entities:  

Mesh:

Year:  1999        PMID: 10547173     DOI: 10.1001/archinte.159.19.2329

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  20 in total

Review 1.  Pre-admission antibiotics for suspected cases of meningococcal disease.

Authors:  Thambu D Sudarsanam; Priscilla Rupali; Prathap Tharyan; Ooriapadickal Cherian Abraham; Kurien Thomas
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease.

Authors:  Moe H Kyaw; Stuart C Clarke; Peter Christie; Ian G Jones; Harry Campbell
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection.

Authors:  Nicole Le Saux; Julie A Bettinger; Susan Wootton; Scott A Halperin; Wendy Vaudry; David W Scheifele; Raymond Tsang
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

5.  Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study.

Authors:  Damien Contou; Romain Sonneville; Florence Canoui-Poitrine; Gwenhaël Colin; Rémi Coudroy; Frédéric Pène; Jean-Marc Tadié; Martin Cour; Gaëtan Béduneau; Antoine Marchalot; Laurent Guérin; Sébastien Jochmans; Stephan Ehrmann; Nicolas Terzi; Sébastien Préau; François Barbier; Guillaume Schnell; Damien Roux; Olivier Leroy; Claire Pichereau; Elodie Gélisse; Lara Zafrani; Richard Layese; Christian Brun-Buisson; Armand Mekontso Dessap; Nicolas de Prost
Journal:  Intensive Care Med       Date:  2018-08-20       Impact factor: 17.440

6.  Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.

Authors:  Caroline L Trotter; W John Edmunds
Journal:  BMJ       Date:  2002-04-06

7.  Relevance of genetically determined host factors to the prognosis of meningococcal disease.

Authors:  P Domingo; E Muñiz-Diaz; M A Baraldès; M Arilla; N Barquet; R Pericas; C Juárez; P Madoz; G Vázquez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-08       Impact factor: 3.267

8.  Management of diagnostic uncertainty in children with possible meningitis: a qualitative study.

Authors:  Cathy A Brennan; Maggie Somerset; Stephen K Granier; Tom P Fahey; Robert S Heyderman
Journal:  Br J Gen Pract       Date:  2003-08       Impact factor: 5.386

Review 9.  Suspicion and treatment of severe sepsis. An overview of the prehospital chain of care.

Authors:  Johan Herlitz; Angela Bång; Birgitta Wireklint-Sundström; Christer Axelsson; Anders Bremer; Magnus Hagiwara; Anders Jonsson; Lars Lundberg; Björn-Ove Suserud; Lars Ljungström
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2012-06-27       Impact factor: 2.953

Review 10.  The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review.

Authors:  Andrea Anonychuk; Gloria Woo; Andrew Vyse; Nadia Demarteau; Andrea C Tricco
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.